Name:	O
___	O
Unit	O
No:	O
___	O
Admission	O
Date:	O
___	O
Discharge	O
Date:	O
___	O
Date	O
of	O
Birth:	O
___	O
Sex:	O
F	O
Service:	O
MEDICINE	O
Allergies:	O
Erythromycin	O
Base	O
/	O
ceftriaxone	O
Attending:	O
___.	O
Chief	O
Complaint:	O
Abdominal	O
Pain	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure:	O
Biliary	O
drain	O
exchange	O
History	O
of	O
Present	O
Illness:	O
___	O
yo	O
F	O
with	O
well-differentiated	O
neuroendocrine	O
tumor	O
s/p	O
TACE	O
x2	O
complicated	O
by	O
necrotic	O
gallbladder	O
s/p	O
CCY	O
and	O
___	O
drainage	O
who	O
presents	O
on	O
transfer	O
from	O
___	O
with	O
abdominal	O
pain.	O
Patient	O
reports	O
worsening	O
RUQ	O
abdominal	O
pain	O
since	O
last	O
___.	O
Pain	O
starts	O
in	O
RUQ	O
and	O
radiates	O
throughout	O
abdomen.	O
Denies	O
associated	O
fever	O
but	O
reports	O
intermittent	O
chills.	O
Denies	O
nausea,	O
vomiting,	O
diarrhea,	O
and	O
constipation.	B-Constipation
Drain	O
in	O
RUQ	O
placed	O
by	O
___	O
has	O
been	O
clamped	O
and	O
not	O
draining	O
for	O
several	O
weeks.	O
Patient	O
states	O
that	O
last	O
time	O
drain	O
dressing	O
was	O
changed	O
by	O
nurse	O
___	O
week),	O
the	O
drain	O
output	O
was	O
higher	O
than	O
prior	O
and	O
color	O
looked	O
"more	O
brown".	O
The	O
patient	O
reports	O
continued	O
pain	O
but	O
similar	O
in	O
nature	O
to	O
prior.	O
In	O
the	O
ED,	O
initial	O
vital	O
signs	O
were	O
98.4,	O
77,	O
116/66,	O
16,	O
96%	O
2	O
L.	O
Labs	O
remarkable	O
for	O
WBC	O
12.5	O
and	O
H/H	O
9.1/___.5.	O
CT	O
abdomen/pelvis	O
with	O
hepatic	O
metastases	O
unchanged	O
from	O
prior	O
and	O
no	O
acute	O
findings.	O
Patient	O
was	O
given	O
IVF	O
and	O
Dilaudid	O
x2	O
and	O
admitted	O
to	O
OMED	O
for	O
symptomatic	O
management	O
of	O
abdominal	O
pain.	O
Review	O
of	O
Systems:	O
As	O
per	O
HPI	O
Past	O
Medical	O
History:	O
Past	O
Oncologic	O
History:	O
___:	O
Pt	O
presented	O
with	O
vague,	O
dull	O
abdominal	O
pain,	O
imaging	O
showed	O
abdominal	O
mass,	O
with	O
lymphadenopathy	O
and	O
liver	O
lesions.	O
Biopsy	O
of	O
the	O
liver	O
lesion	O
demonstrated	O
well	O
differentiated	O
neuroendocrine	O
tumor,	O
metastatic	O
to	O
the	O
liver,	O
originating	O
from	O
the	O
midgut	O
and	O
likely	O
ileum.	O
Pt	O
was	O
asymptomatic	O
and	O
had	O
no	O
episodes	O
of	O
diarrhea,	O
cramping,	O
flushing,	O
tachycardia,	O
hypertension,	O
wheezing	O
or	O
SOB.	O
Pt	O
did	O
endorse	O
fatigue	O
and	O
intentional	O
weight	O
loss	O
of	O
95lb	O
over	O
the	O
course	O
of	O
___	O
years	O
with	O
combined	O
exercise	O
and	O
diet.	O
Her	O
baseline	O
serotonin	O
was	O
in	O
the	O
1000	O
range	O
and	O
the	O
chromogranin	O
was	O
also	O
elevated.	O
Due	O
to	O
the	O
elevated	O
tumor	O
markers,	O
she	O
was	O
started	O
on	O
long	O
acting	O
octreotide	O
injection.	O
Her	O
initial	O
dose	O
was	O
30mg	O
that	O
was	O
increased	O
to	O
40mg	O
after	O
a	O
recent	O
restaging	O
scan	O
that	O
revealed	O
disease	O
progression.	O
On	O
___	O
patient	O
presented	O
to	O
clinic	O
and	O
it	O
was	O
decided	O
that	O
the	O
patient	O
should	O
undergo	O
TACE	O
to	O
'debulk'	O
the	O
amount	O
of	O
active	O
tumor	O
in	O
order	O
to	O
maximize	O
a	O
progression	O
free	O
period	O
and,	O
hopefully,	O
to	O
prolong	O
the	O
amount	O
of	O
time	O
that	O
octreotide	O
is	O
able	O
to	O
control	O
the	O
tumor	O
as	O
a	O
single	O
agent.	O
On	O
___,	O
the	O
patient	O
underwent	O
TACE	O
with	O
complications	O
by	O
E.	O
coli	O
bacteremia	O
and	O
liver	O
abscess.	O
Pt	O
completed	O
3	O
weeks	O
of	O
IV	O
antibiotics	O
and	O
was	O
subsequently	O
discharged	O
to	O
a	O
rehab	O
facility.	O
She	O
was	O
in	O
a	O
rehab	O
facility	O
for	O
approximately	O
3	O
weeks	O
and	O
then	O
was	O
sent	O
home	O
in	O
the	O
end	O
of	O
___.	O
Subsequently,	O
the	O
patient	O
has	O
been	O
followed	O
by	O
Dr.	O
___	O
at	O
___	O
(___)	O
and	O
receiving	O
octreotide	O
injections	O
on	O
a	O
q4,	O
now	O
q3	O
week	O
basis.	O
Other	O
Past	O
Medical	O
History:	O
-	O
Obesity	O
-	O
HTN	O
-	O
Hyperlipidemia	O
-	O
Right	O
shoulder	O
surgery	O
-	O
COPD	B-Lower_respiratory_tract_infection
with	O
multiple	O
admissions	O
for	O
exacerbations/pneumonias	B-Lower_respiratory_tract_infection
(subsided	O
significantly	O
after	O
she	O
quitted	O
smoking)	O
-	O
Back	O
pain	O
-	O
Right	O
foot	O
neuropathy	O
of	O
undetermined	O
etiology	O
-	O
S/p	O
TACE	O
in	O
___	O
-	O
E.	O
Coli	O
bacteremia	O
in	O
___	O
Social	O
History:	O
___	O
Family	O
History:	O
Alcohol	O
abuse	O
in	O
her	O
family,	O
mother	O
is	O
diabetic,	O
brother	O
had	O
early	O
stage	O
lung	O
cancer	O
that	O
was	O
resected	O
decades	O
ago	O
and	O
he	O
is	O
still	O
alive,	O
maternal	O
grandfather	O
died	O
of	O
throat	O
cancer	O
and	O
was	O
a	O
smoker.	O
Her	O
son	O
is	O
prediabetic.	O
Physical	O
Exam:	O
ADMISSION:	O
VS:	O
98,	O
73,	O
105/55,	O
18,	O
96%	O
RA	O
GEN:	O
Chronically-ill	O
appearing	O
elderly	O
female	O
HEENT:	O
NCAT,	O
PERRLA,	O
MMM,	O
oropharynx	O
clear	O
CV:	O
RRR,	O
nl	O
S1/S2,	O
no	O
MRG	O
Pulm:	O
CTAB,	O
no	O
wheezes/rales/rhonchi	O
Abd:	O
Soft,	O
RUQ	O
tenderness,	O
non-distended,	O
no	O
rebound/guarding,	O
normoactive	O
bowel	O
sounds,	O
biliary	O
drain	O
in	O
place	O
Extremities:	O
Warm,	O
well-perfused,	O
2+	O
pitting	O
edema	O
bilaterally	O
Skin:	O
No	O
rashes	O
or	O
bruising	O
Neuro:	O
CN	O
II-XII	O
intact,	O
no	O
concerning	O
lesions	O
DISCHARGE:	O
VS:	O
97.4	O
132/78	O
97	O
18	O
94	O
RA	O
GEN:	O
Chronically-ill	O
appearing	O
elderly	O
female	O
HEENT:	O
NCAT,	O
PERRLA,	O
MMM,	O
oropharynx	O
clear	O
CV:	O
RRR,	O
nl	O
S1/S2,	O
no	O
MRG	O
Pulm:	O
CTAB,	O
no	O
wheezes/rales/rhonchi	O
Abd:	O
Soft,	O
NO	O
RUQ	O
tenderness,	O
non-distended,	O
no	O
rebound/guarding,	O
normoactive	O
bowel	O
sounds,	O
NEW	O
biliary	O
drain	O
in	O
place	O
Extremities:	O
Warm,	O
well-perfused,	O
2+	O
pitting	O
edema	O
bilaterally	O
Skin:	O
No	O
rashes	O
or	O
bruising	O
Neuro:	O
CN	O
II-XII	O
intact,	O
no	O
concerning	O
lesions	O
Pertinent	O
Results:	O
Admission:	O
___	O
01:35AM	O
BLOOD	O
WBC-12.5*#	O
RBC-3.67*	O
Hgb-9.1*	O
Hct-29.5*	O
MCV-80*	O
MCH-24.6*	O
MCHC-30.8*	O
RDW-17.2*	O
Plt	O
___	O
___	O
01:35AM	O
BLOOD	O
Neuts-78.0*	O
Lymphs-12.0*	O
Monos-6.3	O
Eos-3.4	O
Baso-0.3	O
___	O
03:30PM	O
BLOOD	O
Glucose-96	O
UreaN-11	O
Creat-0.8	O
Na-132*	O
K-4.0	O
Cl-97	O
HCO3-26	O
AnGap-13	O
___	O
03:30PM	O
BLOOD	O
ALT-34	O
AST-47*	O
AlkPhos-668*	O
TotBili-0.5	O
___	O
03:30PM	O
BLOOD	O
Calcium-9.1	O
Phos-3.3	O
Mg-2.1	O
___	O
03:30PM	O
BLOOD	O
Calcium-9.1	O
Phos-3.3	O
Mg-2.1	O
___	O
03:32PM	O
BLOOD	O
___	O
pO2-40*	O
pCO2-51*	O
pH-7.31*	O
calTCO2-27	O
Base	O
XS--1	O
Comment-GREEN	O
TOP	O
___	O
01:43AM	O
BLOOD	O
Lactate-1.2	O
Discharge:	O
___:40AM	O
BLOOD	O
WBC-9.9	O
RBC-3.78*	O
Hgb-9.7*	O
Hct-30.0*	O
MCV-79*	O
MCH-25.6*	O
MCHC-32.3	O
RDW-15.1	O
Plt	O
___	O
___	O
06:40AM	O
BLOOD	O
___	O
PTT-32.0	O
___	O
___	O
06:40AM	O
BLOOD	O
Glucose-105*	O
UreaN-9	O
Creat-0.7	O
Na-133	O
K-4.2	O
Cl-100	O
HCO3-24	O
AnGap-13	O
___	O
06:40AM	O
BLOOD	O
ALT-27	O
AST-47*	O
LD(LDH)-135	O
AlkPhos-690*	O
TotBili-0.6	O
___	O
06:40AM	O
BLOOD	O
Albumin-2.9*	O
Calcium-9.1	O
Phos-3.4	O
Mg-2.1	O
Urine:	O
___	O
04:12AM	O
URINE	O
Color-Yellow	O
Appear-Clear	O
Sp	O
___	O
___	O
04:12AM	O
URINE	O
Blood-NEG	O
Nitrite-NEG	O
Protein-TR	O
Glucose-NEG	O
Ketone-NEG	O
Bilirub-NEG	O
Urobiln-NEG	O
pH-6.5	O
Leuks-NEG	O
___	O
04:12AM	O
URINE	O
RBC-<1	O
WBC-<1	O
Bacteri-FEW	O
Yeast-NONE	O
Epi-1	O
TransE-<1	O
Blood	O
culture	O
pending	O
CT	O
ABD	O
PELVIS	O
W/	O
CONTRAST	O
___:	O
1.	O
Essentially	O
unchanged	O
appearance	O
of	O
multiple	O
hepatic	O
metastases	O
and	O
pancreatic	O
head	O
mass	O
encasing	O
the	O
SMA.	O
2.	O
Internal-external	O
biliary	O
drain	O
terminates	O
in	O
the	O
third	O
portion	O
of	O
the	O
duodenum,	O
and	O
previously	O
seen	O
fluid	O
collection	O
along	O
the	O
drain	O
has	O
resolved.	O
No	O
new	O
intrahepatic	O
or	O
perihepatic	O
collections	O
are	O
identified.	O
3.	O
Continued	O
retroperitoneal	O
and	O
pelvic	O
lymphadenopathy	O
in	O
keeping	O
with	O
known	O
metastatic	O
disease.	O
___	O
GUIDED	O
CHOLANGIOGRAM	O
AND	O
DRAIN	O
EXCHANGE	O
___:	O
(Preliminary	O
Report)	O
IMPRESSION:	O
1.	O
Mild	O
inward	O
migration	O
of	O
the	O
existing	O
biliary	O
drainage	O
catheter.	O
2.	O
Cholangiogram	O
demonstrates	O
small	O
amount	O
of	O
contrast	O
leak	O
from	O
the	O
cystic	O
duct	O
stump.	O
3.	O
Prolonged	O
contrast	O
transit	O
through	O
the	O
ampulla	O
suggestive	O
of	O
ampullary	O
edema/	O
stricture.	O
4.	O
Successful	O
exchange	O
of	O
existing	O
percutaneous	O
transhepatic	O
biliary	O
drainage	O
catheter	O
with	O
new	O
12	O
___	O
catheter.	O
5.	O
No	O
drainable	O
fluid	O
around	O
the	O
tube	O
entry	O
site.	O
Brief	O
Hospital	O
Course:	O
HOSPITAL	O
COURSE:	O
___	O
F	O
with	O
well-differentiated	O
neuroendocrine	O
tumor	O
s/p	O
TACE	O
x2	O
complicated	O
by	O
necrotic	O
gallbladder	O
s/p	O
CCY	O
and	O
___	O
drainage	O
who	O
presents	O
from	O
___	O
with	O
abdominal	O
pain.	O
No	O
infection	O
of	O
other	O
process	O
noted.	O
___	O
replaced	O
tube	O
which	O
was	O
misplaced	O
and	O
patient	O
felt	O
better	O
on	O
home	O
pain	O
medications.	O
Dc-ed	O
home	O
for	O
outpatient	O
followup	O
ACTIVE	O
ISSUES:	O
#	O
Abdominal	O
pain:	O
patient	O
has	O
pain	O
in	O
abdomen	O
and	O
at	O
site	O
of	O
drain.	O
No	O
peritoneal	O
signs	O
and	O
pain	O
reasonably	O
well	O
controlled	O
with	O
home	O
pain	O
regimen.	O
Lacate	O
is	O
1.2	O
making	O
gut	O
necrosis	O
unlikely.	O
___	O
looked	O
at	O
CT	O
and	O
thought	O
drain	O
had	O
migrated	O
so	O
exchanged	O
it	O
for	O
___	O
drain.	O
Patient	O
did	O
well	O
post	O
procedure.	O
No	O
infection/abscess	O
noted	O
during	O
___	O
procedure.	O
-	O
Continued	O
on	O
home	O
OxyCODONE	O
SR	O
(OxyconTIN)	O
20	O
mg	O
PO	O
Q12H	O
and	O
HYDROmorphone	O
(Dilaudid)	O
___	O
mg	O
PO/NG	O
Q3H:PRN	O
pain	O
at	O
home	O
-	O
also	O
having	O
gas	O
pain	O
so	O
continued	O
home	O
simethicone	O
-	O
no	O
evidence	O
of	O
infection	O
at	O
present	O
INACTIVE	O
ISSUES:	O
#	O
Neuroendocrine	O
tumor:	O
Diease	O
progression	O
on	O
octreotide	O
was	O
demonstrated	O
on	O
CT	O
scan	O
today.	O
-	O
corresponded	O
with	O
Dr	O
___	O
further	O
decision	O
making:	O
outpatient	O
management	O
#	O
Leg	O
swelling:	O
has	O
had	O
singifcant	O
bilateral	O
pedal	O
edema	O
since	O
last	O
TACE	O
2X2	O
immobilization.	O
-	O
continued	O
home	O
lasix	O
20mg	O
qd	O
-	O
pt	O
consulted:	O
cleared	O
for	O
home	O
with	O
___	O
#	O
Hypertension:	O
stable	O
-	O
continued	O
home	O
Metoprolol	O
Tartrate	O
12.5	O
mg	O
PO	O
BID	O
#	O
Hyperlipidemia:	O
stable	O
-	O
continued	O
home	O
simva	O
10mg	O
qd	O
#	O
COPD:	O
stable	O
on	O
RA	O
-	O
continued	O
Albuterol	O
0.083%	O
Neb	O
Soln	O
1	O
NEB	O
IH	O
Q6H:PRN	O
and	O
Fluticasone-Salmeterol	O
Diskus	O
(500/50)	O
1	O
INH	O
IH	O
BID	O
and	O
Ipratropium-Albuterol	O
Inhalation	O
Spray	O
1	O
INH	O
IH	O
BID:PRN	O
#	O
Constipation:	B-Constipation
stable	O
-	O
continued	O
home	O
Bisacodyl	O
___AILY,	O
Docusate	O
Sodium	O
100	O
mg	O
PO	O
BID,	O
Milk	O
of	O
Magnesia	O
30	O
mL	O
PO	O
Q6H:PRN,	O
Polyethylene	O
Glycol	O
17	O
g	O
PO	O
DAILY:PRN	O
and	O
Senna	O
8.6	O
mg	O
PO	O
BID	O
#	O
Vitamin	O
supplementation:	O
stable	O
-	O
continued	O
home	O
Ascorbic	O
Acid	O
___	O
mg	O
PO	O
DAILY,	O
Fish	O
Oil	O
(Omega	O
3)	O
1000	O
mg	O
PO	O
DAILY,	O
Multivitamins	O
1	O
TAB	O
PO	O
DAILY,	O
Vitamin	O
D	O
1000	O
UNIT	O
PO	O
DAILY	O
and	O
Vitamin	O
E	O
400	O
UNIT	O
PO	O
DAILY	O
#	O
GERD:	O
stable	O
-	O
continued	O
home	O
tums	O
and	O
omeprazole	O
#	O
Hypothyroid:	O
stable	O
-	O
continued	O
home	O
levothyroxine	O
#	O
Depression:	O
stable	O
-	O
continued	O
home	O
escitalopram	O
TRANSITIONAL	O
ISSUES:	O
-	O
NO	O
PAIN	O
MED	O
CHANGES	O
Medications	O
on	O
Admission:	O
The	O
Preadmission	O
Medication	O
list	O
is	O
accurate	O
and	O
complete.	O
1.	O
Acetaminophen	O
650	O
mg	O
PO	O
Q6H:PRN	O
pain	O
2.	O
Ascorbic	O
Acid	O
___	O
mg	O
PO	O
DAILY	O
3.	O
Calcium	O
Carbonate	O
500	O
mg	O
PO	O
QID:PRN	O
indigestion	O
4.	O
Fish	O
Oil	O
(Omega	O
3)	O
1000	O
mg	O
PO	O
DAILY	O
5.	O
Fluticasone	O
Propionate	O
NASAL	O
1	O
SPRY	O
NU	O
DAILY	O
6.	O
Fluticasone-Salmeterol	O
Diskus	O
(500/50)	O
1	O
INH	O
IH	O
BID	O
7.	O
HYDROmorphone	O
(Dilaudid)	O
___	O
mg	O
PO	O
Q3H:PRN	O
pain	O
8.	O
Levothyroxine	O
Sodium	O
75	O
mcg	O
PO	O
DAILY	O
9.	O
Metoprolol	O
Tartrate	O
12.5	O
mg	O
PO	O
BID	O
10.	O
Milk	O
of	O
Magnesia	O
30	O
mL	O
PO	O
Q6H:PRN	O
constipation	B-Constipation
11.	O
Multivitamins	O
1	O
TAB	O
PO	O
DAILY	O
12.	O
Polyethylene	O
Glycol	O
17	O
g	O
PO	O
DAILY:PRN	O
constipation	B-Constipation
13.	O
Senna	O
8.6	O
mg	O
PO	O
BID	O
14.	O
Simethicone	O
40-80	O
mg	O
PO	O
QID:PRN	O
gas	O
pains	O
15.	O
Simvastatin	O
10	O
mg	O
PO	O
DAILY	O
16.	O
TraZODone	O
25	O
mg	O
PO	O
HS:PRN	O
insomnia	O
17.	O
Vitamin	O
D	O
1000	O
UNIT	O
PO	O
DAILY	O
18.	O
Bisacodyl	O
___AILY	O
constipation	B-Constipation
19.	O
Docusate	O
Sodium	O
100	O
mg	O
PO	O
BID	O
20.	O
Ipratropium-Albuterol	O
Inhalation	O
Spray	O
1	O
INH	O
IH	O
BID:PRN	O
SOB	O
21.	O
lutein	O
6	O
mg	O
Oral	O
daily	O
22.	O
Vitamin	O
E	O
400	O
UNIT	O
PO	O
DAILY	O
23.	O
OxyCODONE	O
SR	O
(OxyconTIN)	O
20	O
mg	O
PO	O
Q12H	O
24.	O
Furosemide	O
20	O
mg	O
PO	O
DAILY	O
25.	O
SandoSTATIN	O
LAR	O
Depot	O
(octreotide	O
acetate)	O
40	O
mg	O
injection	O
Q3W	O
26.	O
Aspirin	O
81	O
mg	O
PO	O
DAILY	O
27.	O
Escitalopram	O
Oxalate	O
10	O
mg	O
PO	O
DAILY	O
28.	O
Omeprazole	O
20	O
mg	O
PO	O
DAILY	O
29.	O
Albuterol	O
0.083%	O
Neb	O
Soln	O
1	O
NEB	O
IH	O
Q6H:PRN	O
SOB	O
Discharge	O
Medications:	O
1.	O
Acetaminophen	O
650	O
mg	O
PO	O
Q6H:PRN	O
pain	O
2.	O
Albuterol	O
0.083%	O
Neb	O
Soln	O
1	O
NEB	O
IH	O
Q6H:PRN	O
SOB	O
3.	O
Ascorbic	O
Acid	O
___	O
mg	O
PO	O
DAILY	O
4.	O
Aspirin	O
81	O
mg	O
PO	O
DAILY	O
5.	O
Bisacodyl	O
___AILY	O
constipation	B-Constipation
6.	O
Calcium	O
Carbonate	O
500	O
mg	O
PO	O
QID:PRN	O
indigestion	O
7.	O
Docusate	O
Sodium	O
100	O
mg	O
PO	O
BID	O
8.	O
Escitalopram	O
Oxalate	O
10	O
mg	O
PO	O
DAILY	O
9.	O
Fish	O
Oil	O
(Omega	O
3)	O
1000	O
mg	O
PO	O
DAILY	O
10.	O
Fluticasone	O
Propionate	O
NASAL	O
1	O
SPRY	O
NU	O
DAILY	O
11.	O
Fluticasone-Salmeterol	O
Diskus	O
(500/50)	O
1	O
INH	O
IH	O
BID	O
12.	O
Furosemide	O
20	O
mg	O
PO	O
DAILY	O
13.	O
HYDROmorphone	O
(Dilaudid)	O
___	O
mg	O
PO	O
Q3H:PRN	O
pain	O
14.	O
Ipratropium-Albuterol	O
Inhalation	O
Spray	O
1	O
INH	O
IH	O
BID:PRN	O
SOB	O
15.	O
Levothyroxine	O
Sodium	O
75	O
mcg	O
PO	O
DAILY	O
16.	O
Metoprolol	O
Tartrate	O
12.5	O
mg	O
PO	O
BID	O
17.	O
Milk	O
of	O
Magnesia	O
30	O
mL	O
PO	O
Q6H:PRN	O
constipation	B-Constipation
18.	O
Multivitamins	O
1	O
TAB	O
PO	O
DAILY	O
19.	O
Omeprazole	O
20	O
mg	O
PO	O
DAILY	O
20.	O
OxyCODONE	O
SR	O
(OxyconTIN)	O
20	O
mg	O
PO	O
Q12H	O
21.	O
Polyethylene	O
Glycol	O
17	O
g	O
PO	O
DAILY:PRN	O
constipation	B-Constipation
22.	O
Senna	O
8.6	O
mg	O
PO	O
BID	O
23.	O
Simethicone	O
40-80	O
mg	O
PO	O
QID:PRN	O
gas	O
pains	O
24.	O
Simvastatin	O
10	O
mg	O
PO	O
DAILY	O
25.	O
TraZODone	O
25	O
mg	O
PO	O
HS:PRN	O
insomnia	O
26.	O
Vitamin	O
D	O
1000	O
UNIT	O
PO	O
DAILY	O
27.	O
Vitamin	O
E	O
400	O
UNIT	O
PO	O
DAILY	O
28.	O
lutein	O
6	O
mg	O
Oral	O
daily	O
29.	O
Octreotide	O
LAR	O
Depot	O
(octreotide	O
acetate)	O
40	O
mg	O
INJECTION	O
Q3W	O
Discharge	O
Disposition:	O
Home	O
With	O
Service	B-Has_carers
Facility:	O
___	O
Discharge	O
Diagnosis:	O
Biliary	O
Stenosis	O
Gallbladder	O
Necrosis	O
Neuroendocrine	O
Tumor	O
Discharge	O
Condition:	O
Mental	O
Status:	O
Clear	B-Delirium
and	B-Delirium
coherent.	B-Delirium
Level	O
of	O
Consciousness:	O
Alert	O
and	O
interactive.	O
Activity	O
Status:	O
Ambulatory	B-Mobile_with_assistance
-	B-Mobile_with_assistance
requires	B-Mobile_with_assistance
assistance	B-Mobile_with_assistance
or	O
aid	B-Mobile_with_aid
(walker	O
or	O
cane).	O
Discharge	O
Instructions:	O
You	O
were	O
admitted	O
to	O
___	O
with	O
pain	O
and	O
your	O
biliary	O
tube	O
was	O
found	O
to	O
be	O
slightly	O
misplaced.	O
The	O
tube	O
was	O
replaced	O
with	O
a	O
new	O
one	O
and	O
you	O
felt	O
better.	O
You	O
were	O
discharged	O
home	O
for	O
further	O
care	O
as	O
an	O
outpatient.	O
Followup	O
Instructions:	O
___	O

